Samandhy Cedeño Briceño
Senior research technician
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.